Price and VolumeDetailed Quote
Top NewsMore News![]() Performance
More NewsRead More![]()
The Analyst Landscape: 7 Takes On Alkermes
June 17, 2024
Via Benzinga
![]() ![]()
6 Analysts Assess Alkermes: What You Need To Know
May 23, 2024
Via Benzinga
![]()
7 Analysts Assess Alkermes: What You Need To Know
May 02, 2024
Via Benzinga
![]() Via Chartmill
![]() Via Chartmill
![]()
Breaking Down Alkermes: 5 Analysts Share Their Views
April 09, 2024
Via Benzinga
![]() ![]() ![]() Via Benzinga
![]() ![]()
Is NASDAQ:ALKS suited for growth investing?
March 20, 2024
Via Chartmill
![]()
The Analyst Verdict: Alkermes In The Eyes Of 4 Experts
March 19, 2024
Via Benzinga
![]()
Exploring NASDAQ:ALKS's growth characteristics.
February 28, 2024
Via Chartmill
![]()
A Look Into Healthcare Sector Value Stocks
March 11, 2024
Via Benzinga
![]()
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
![]() ![]()
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
![]() ![]() ![]()
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
February 15, 2024
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|